“Name one thing, just one thing, that Dr. Rahman has done for the company. Can anyone?”
Now starts the spin on how investors didn’t like Dr. Rahman anyways and how he didn’t do anything and how he wasn’t worth the shares anyways. Many, many investors, including myself, were happy to have Dr. Rahman on board as he had real biotech experience compared to the amateurs, NP and SK. He’d even been a part of drug approvals in the past, which is more than the entity of CYDY can speak for. His departure is not good news, IMO, as now someone else had to figure out the HIV BLA, which according to NP today, is still somewhat a mess.